Expert Consensus on the Optimal Management of BRAF-mutant Metastatic Colorectal Cancer in the Asia-Pacific Region

Overview

Journal Asia Pac J Clin Oncol

Specialty Oncology

Date 2024 Oct 26

PMID 39456063

Authors

Oliver Piercey

Lorraine Chantrill

Hung-Chih Hsu

Brigette Ma

Timothy Price

Iain Beehuat Tan

Hao-Wei Teng

Jeanne Tie

Jayesh Desai

Affiliations

Soon will be listed here.

Abstract

The burden of colorectal cancer (CRC) is high in the Asia-Pacific region, and several countries in this region have among the highest and/or fastest growing rates of CRC in the world. A significant proportion of patients will present with or develop metastatic CRC (mCRC), and BRAF-mutant mCRC represents a particularly aggressive phenotype that is less responsive to standard chemotherapies. In light of recent therapeutic advances, an Asia-Pacific expert consensus panel was convened to develop evidence-based recommendations for the diagnosis, treatment, and management of patients with BRAF-mutant mCRC. The expert panel comprised nine medical oncologists from Australia, Hong Kong, Singapore, and Taiwan (the authors), who met to review current literature and develop eight consensus statements that describe the optimal management of BRAF-mutant mCRC in the Asia-Pacific region. As agreed by the expert panel, the consensus statements recommend molecular testing at diagnosis to guide individualized treatment decisions, propose optimal treatment pathways according to microsatellite stability status, advocate for more frequent monitoring of BRAF-mutant mCRC, and discuss local treatment strategies for oligometastatic disease. Together, these expert consensus statements are intended to optimize treatment and improve outcomes for patients with BRAF-mutant mCRC in the Asia-Pacific region.

Citing Articles

Real-World Data of Patients with V600E-Mutated Metastatic Colorectal Cancer Treated with Trifluridine/Tipiracil.

Ros J, Ucha J, Garcia-Galea E, Gomez P, Martini G, Balconi F Cancers (Basel). 2025; 16(24.

PMID: 39766040 PMC: 11674344. DOI: 10.3390/cancers16244140.

Expert consensus on the optimal management of BRAF-mutant metastatic colorectal cancer in the Asia-Pacific region.

Piercey O, Chantrill L, Hsu H, Ma B, Price T, Tan I Asia Pac J Clin Oncol. 2024; 21(1):31-45.

PMID: 39456063 PMC: 11733838. DOI: 10.1111/ajco.14132.

References

Morris V, Overman M, Jiang Z, Garrett C, Agarwal S, Eng C . Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. Clin Colorectal Cancer. 2014; 13(3):164-71. PMC: 4266576. DOI: 10.1016/j.clcc.2014.06.001. View

Araghi M, Soerjomataram I, Bardot A, Ferlay J, Cabasag C, Morrison D . Changes in colorectal cancer incidence in seven high-income countries: a population-based study. Lancet Gastroenterol Hepatol. 2019; 4(7):511-518. PMC: 7617144. DOI: 10.1016/S2468-1253(19)30147-5. View

Young J, Win A, Rosty C, Flight I, Roder D, Young G . Rising incidence of early-onset colorectal cancer in Australia over two decades: report and review. J Gastroenterol Hepatol. 2014; 30(1):6-13. DOI: 10.1111/jgh.12792. View

Corcoran R, Ebi H, Turke A, Coffee E, Nishino M, Cogdill A . EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2012; 2(3):227-35. PMC: 3308191. DOI: 10.1158/2159-8290.CD-11-0341. View

Lungulescu C, Ungureanu B, Turcu-Stiolica A, Ghimpau V, Artene S, Cazacu I . The role of IgE specific for galactose-α-1,3-galactose in predicting cetuximab induced hypersensitivity reaction: a systematic review and a diagnostic meta-analysis. Sci Rep. 2020; 10(1):21355. PMC: 7721698. DOI: 10.1038/s41598-020-78497-7. View

Bellio H, Fumet J, Ghiringhelli F . Targeting BRAF and RAS in Colorectal Cancer. Cancers (Basel). 2021; 13(9). PMC: 8124706. DOI: 10.3390/cancers13092201. View

Ye L, Huang Z, Chen X, Chen Z, Wu S, Ren C . Monitoring tumour resistance to the BRAF inhibitor combination regimen in colorectal cancer patients via circulating tumour DNA. Drug Resist Updat. 2022; 65:100883. DOI: 10.1016/j.drup.2022.100883. View

Yoshino T, Cervantes A, Bando H, Martinelli E, Oki E, Xu R . Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer. ESMO Open. 2023; 8(3):101558. PMC: 10220270. DOI: 10.1016/j.esmoop.2023.101558. View

Roed Skarderud M, Polk A, Vistisen K, Larsen F, Nielsen D . Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: A systematic review. Cancer Treat Rev. 2017; 62:61-73. DOI: 10.1016/j.ctrv.2017.10.011. View

10.

Morgan E, Arnold M, Gini A, Lorenzoni V, Cabasag C, Laversanne M . Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut. 2023; 72(2):338-344. DOI: 10.1136/gutjnl-2022-327736. View

11.

Morkel M, Riemer P, Blaker H, Sers C . Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance. Oncotarget. 2015; 6(25):20785-800. PMC: 4673229. DOI: 10.18632/oncotarget.4750. View

12.

Wang J, Li S, Liu Y, Zhang C, Li H, Lai B . Metastatic patterns and survival outcomes in patients with stage IV colon cancer: A population-based analysis. Cancer Med. 2019; 9(1):361-373. PMC: 6943094. DOI: 10.1002/cam4.2673. View

13.

Xu J, Kim T, Shen L, Sriuranpong V, Pan H, Xu R . Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study. J Clin Oncol. 2017; 36(4):350-358. DOI: 10.1200/JCO.2017.74.3245. View

14.

Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P . Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008; 26(35):5705-12. DOI: 10.1200/JCO.2008.18.0786. View

15.

Diaz Jr L, Shiu K, Kim T, Jensen B, Jensen L, Punt C . Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 2022; 23(5):659-670. PMC: 9533375. DOI: 10.1016/S1470-2045(22)00197-8. View

16.

de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J . Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000; 18(16):2938-47. DOI: 10.1200/JCO.2000.18.16.2938. View

17.

Jones J, Renfro L, Al-Shamsi H, Schrock A, Rankin A, Zhang B . BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer. J Clin Oncol. 2017; 35(23):2624-2630. PMC: 5549454. DOI: 10.1200/JCO.2016.71.4394. View

18.

Tol J, Nagtegaal I, Punt C . BRAF mutation in metastatic colorectal cancer. N Engl J Med. 2009; 361(1):98-9. DOI: 10.1056/NEJMc0904160. View

19.

Baratti D, Kusamura S, Niger M, Perrone F, Milione M, Cattaneo L . Prognostic Impact of Primary Side and RAS/RAF Mutations in a Surgical Series of Colorectal Cancer with Peritoneal Metastases. Ann Surg Oncol. 2020; 28(6):3332-3342. DOI: 10.1245/s10434-020-09161-7. View

20.

Tian J, Chen J, Chao S, Pelka K, Giannakis M, Hess J . Combined PD-1, BRAF and MEK inhibition in BRAF colorectal cancer: a phase 2 trial. Nat Med. 2023; 29(2):458-466. PMC: 9941044. DOI: 10.1038/s41591-022-02181-8. View